TGFB1 and pulmonary arterial hypertension: Given the recent success of specific TGFβ blockers in other vascular disorders such as pulmonary arterial hypertension (PAH) and restenosis, targeting the TGFβ pathway more directly could be a strategy for developing new treatment modalities for TAA (Yao et al., 2009; Yung et al., 2016).